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1.  INTRodUCTIoN
Most of the organophosphorous (OP) compounds are 
cholinesterase (ChE) inhibitors and extremely toxic. Some of 
the OP compounds are regarded as nerve agents and are listed 
in the schedules of the chemical weapons convention. The 
deleterious actions of nerve agents and related OP pesticides 
are due to their ability to potently inhibit acetylcholinesterase 
(AChE) irreversibly, that leads to accumulation of acetylcholine 
in synaptic cleft and further to cholinergic crisis1,2. There is still 
a possibility of deliberate use of OP compounds on humans with 
the	primary	 intention	of	 inflicting	a	casualty	or	 reducing	 the	
combat	efficiency	during	war	and	by	terrorists3-6. OP or nerve 
agent	intoxication	can	be	readily	identified	by	its	characteristic	
signs and symptoms such as constriction of pupil (miosis), 
hypersecretion, tremors and convulsions7,8. The most critical 
effects of nerve agent exposure are paralysis of respiratory 
muscles and inhibition of respiratory centre that leads to 
death9. Death is immediate on high dose exposure of toxicants, 
the only solution is immediate administration of atropine 
sulphate	followed	by	pralidoxime	chloride	(2	[(hydroxyimino)	
methyl]-1-methylpyridinium	chloride)10. Atropine sulphate is 
a competitive inhibitor of muscarinic receptor and pralidoxime 
chloride (PAM Cl) acts as an acetylcholine esterase reactivator. 
In	the	field	presence	of	medical	personnel	for	immediate	drug	
administration during the exposure of nerve agents is not 
possible, for such emergencies self injectable autoinjectors 
containing drugs are in vogue, and are designed to permit a 
rapid and convenient means of intramuscular administration of 
the drugs10-14. This establishment has designed and developed 
the reusable autoject injectors in which the cartridges can be 
replaced after the expiry of shelf life of the drug (Fig. 1)13. It 
has generally been considered that pralidoxime chloride is less 
stable in solution compared to atropine sulphate. The antidotal 
effectiveness of PAM Cl in autoinjector was reported against 
sarin,	dichlorvas	(DDVP)	and	diisopyropylphosphorofluridate	
(DFP), and found to be stable up to three years13-15. Three 
sets of two autoinjectors are provided to army persons for 
administration of required amount of PAM Cl (~1800 mg) 
along with atropine sulphate (~ 6 mg)16. In an emergency it is 
possible that soldiers may get confused which one should be 
used	first.	With	the	view	of	replacing	six	autoinjectors	by	three	
we have combined atropine sulphate (1 mg/ml) and PAM Cl 
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Figure 1. Traditional indigenous designed autoject-injector 
containing PAM Cl and atropine sulphate drugs for 
nerve agent poisoning.
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(300 mg/ml) in a single drug cartridge for autoinjector. This 
combination has come out as a new formulation thus we  have 
calculated the shelf life by accelerated stability testing as well 
as evaluated the biological activity of both the antidotes in 
separate models. The current regulations for stability tests are 
drafted by the International Commission for Harmonisation 
(ICH)17,18. Accelerated testing at high temperatures allows a 
significant	reduction	in	testing	time.	The	stress	testing	includes	
the effect of temperature in 10 °C increments as an accelerated 
temperature mode for the shelf life prediction of drug using 
Arrhenius theory.
The recommended storage condition for autoinjector is 
preferably 25 °C or less. The climatic conditions are highly 
variable in several parts of the world. The possible temperature 
and	 humidity	 fluctuations	 outside	 the	 labeled	 storage	
conditions affect the drug. The objective of present work is to 
make a reliable stability prediction for pralidoxime chloride 
and atropine sulphate in combination with self-injectable 
autoinjector drug cartridges for OP or nerve agent toxicity. 
2. ExPERIMENT 
2.1 Materials and Methods
Pralidoxime chloride and atropine sulphate were of 
Indian Pharmacopoeia (IP) grade, purchased from trade. 
Acetonitrile	(HPLC	grade)	was	purchased	from	J.T.	Baker	
chemicals (India). DDVP was purchased from the trade. 
All other chemicals were of pharmaceutical or analytical 
grade and obtained from Qualigens (India) or Ranbaxy 
Fine Chemicals (India). For autoinjector cartridge materials 
viz., borosilicate glass cartridge (Borosilicate, India), 
bromobutyl septums (Bharat Rubber, India), and stainless 
steel needles (Iscon Engineering, India) were used.
2.2 Cartridges Preparation
Glass cartridge, convoluted needle and the septums were 
sterilized in a steam sterilizer. The needle was introduced in the 
glass cartridge and the back septum was placed and aligned. 
Pralidoxime chloride (300 mg/ml) along with atropine sulphate 
(1 mg/ml) was prepared in methyl paraben (1%w/v) and 
filtered	through	a	0.22	-µm	membrane	filters	(Millipore	Corp.,	
Mass,	uSA).	The	final	pH	of	drug	solution	was	4.0-4.5	and	2.2	
ml	of	drug	solution	was	filled	in	the	glass	cartridges,	covered	
with the front septum under nitrogen purging and sealed with 
an aluminium cap using the hand operated crimping device. 
A set of 10 autoinjector containing the cartridges was used 
for the study and each were kept in a photostability chamber 
(Thermolabs	 Scientific,	 India)	 with	 65	 %	 (±	 5	 %)	 relative	
humidity as follows:
Group I :  stored at 30 °C 
Group II:  stored at 40 °C.
Group II:  stored at 50 °C  
Group IV:  stored at 60 °C
2.3 Assay of Pralidoxime Chloride 
Aliquots of   samples for chemical assay were withdrawn 
aseptically at the required intervals using a Hamilton syringe 
through out the study. The solution was subjected to assay 
procedure as per Indian Pharmacopoeia (IP). In brief, an 
aliquot was diluted with distilled water to a concentration of 
100	 µg/ml,	 and	 then	 re-diluted	 with	 1N	NaOH to obtain a 
final	concentration	of	10	µg/ml.	Samples	were	assayed	by	uV	
analysis at 332 nm using a spectronic 1201 spectrophotometer 
(Spectronic Corporation, USA) within 10 minutes after the 
addition of NaOH. Standard solutions were prepared by 
dissolving reference standard in distilled water for making 
samples of various concentrations (50 mg/ml – 400 mg/ml). 
Atropine sulphate has not given any absorbance when followed 
by the same procedure that indicates no interference of atropine 
in the estimation of PAM Cl.
2.3.1 In-vivo Protection Studies Against DDVP
Randomly bred Swiss female mice (30-35 g) from 
the Institute’s animal facility were used for the study. The 
animals were housed in polypropylene cages under controlled 
experimental conditions with free access to food (standard 
pellet	 diet,	Ashirwad	 Ltd,	 India)	 and	water	 until	 2	 h	 before	
and after the experiment. The care and maintenance of the 
animals were carried out as per the approved guidelines of 
the Committee for the Purpose of Control and Supervision of 
Experiments on Animals (CPCSEA, India).This study has the 
approval of the Institutional Animal Ethical Committee. 
This study is designed to assess the bioactivity of PAM 
Cl stored at various temperatures in combination with atropine 
sulphate in autoinjector drug cartridges. This study was carried 
out according to the method reported by Kumar14, et al. 
Protective index (PI) was determined by the given formula:
In brief, for this study each group consisted of ten mice. 
Mice were treated with PAM Cl (30 mg/kg) and atropine 
sulphate (10 mg/kg) after DDVP (80 mg/kg, 160 mg/kg and 320 
mg/kg, s.c)  administration and observed up to 24 hrs for any 
mortality. For this study freshly prepared solution of atropine 
sulphate was used and for PAM Cl,  required volume of the 
sample was taken from the prepared cartridges aseptically and 
diluted in water for injection (WFI).  Both atropine sulphate 
and PAM Cl were injected immediately after injecting various 
doses of DDVP and PI was calculated according to previous 
reports14. The PI of stored samples was compared to PI of 
freshly prepared sample and per cent activity of PAM Cl was 
calculated.
2.4 Assay of Atropine Sulphate
The concentration of atropine sulphate was assayed 
according to the method reported by Vijayaraghavan13, et al. 
with	slight	modifications.	Waters	(600	controller)	HPLC	system	
consisted	of	rheodyne	manual	injector	with	10	µl	sample	loop	
with Waters Xterra MS C18 column was used for drug assay. 
Mobile phase consisted of 50 mM phosphate buffer (KH2PO4, 
pH 3.2 with Phosphoric acid) and acetonitrile (85+15). Sample 
was run at 22 °C column temperature and absorbance was 
recorded at 211 nm by 2487 UV detector. In the same mobile 
phase PAM Cl has not given any peak. 
2.4.1 In-vitro Bioassay of Atropine Sulphate
 Atropine sulphate was assayed by its muscarinic receptor 
blocking action. The percent blocking effect of acetylcholine 
(ACh) was determined on rat’s isolated ileal muscle in vitro 
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in isolated organ bath. Isolated segment of rat’s distal ileum, 
1.5 cm to 2 cm in length, was vertically suspended in oxygenated 
Krebs’ solution in 30 ml organ bath. The temperature of the 
bath was maintained at 36 °C. Before the administration of any 
drug, the tissues were stabilised at a resting tension of 0.5-1 g 
and equilibrated for 30 min washing out every 10 min.
Acetylcholine was dissolved in distilled water and added 
to the organ tube of bath. In all cases, after the maximal 
contractile effect had been obtained (1 min), the preparation 
was	washed	by	an	overflow	perfusion	of	bath	with	30–60	ml	
of Kreb’s ringer solution, and the chamber was continuously 
superfused between drug administrations. Concentrations are 
expressed	as	final	drug	concentrations	(e.g.	ACh	1,	2,	and	4	
µg/ml)	 actually	 in	 contact	with	 ileum	 tissue,	 and	 cover	 the	
full range from no effect to maximal contractile response. For 
selection of atropine sulphate (e.g. 1, 2, 4 ng/ml) dose in a 
separate set of experiments, it was added 10 min prior to ACh 
(1,	2	and	4	µg/ml)	in	three	different	doses.	Atropine	sulphate	
in dose of 2 ng/ml was found to block the effect of ACh in 
all three doses and this dose is selected for further studies 
(Table 2). 
3. CAlCUlATIoN oF SHElF lIFE
For	 the	 first	 order	 reaction	 the	 rate	 constant	 at	 various	
temperature was noted from the slope of the graph by the 
formula:
Slope  =  –K / 2.303
The recorded rate constant at various temperatures are 
given in Table 1. From the slope of the graph and rate constant 
the degradation rate was calculated.
The Arrhenius plot was drawn for the logarithm of velocity 
constant against the reciprocal of the absolute temperature. 
aE RTK Ae−=
where Ea is the activation energy, A is the Arrhenius constant, R 
is the molar gas constant and T is the absolute temperature.
The K value at desired temperature of 25 °C was obtained 
by extrapolating the Arrhenius plot. The obtained K value was 
then	placed	in	the	first	order	equation	and	t	90% was calculated 
from equation:
0log log 2.303C C Kt= −  
where C is the potency at time t, and C0 is potency at time t0
90%
log(100 / 90) 2.303t
K
×=
 
4. STATISTICAl ANAlySIS
All the variables were analyzed by one-way ANOVA with 
student Newman-Keuls multiple comparison procedure. A 
probability	of	<0.05	is	taken	as	statistically	significant.	Sigma	
Stat (Jandel Sci. USA) was used for statistical calculations. 
5. RESUlTS ANd dISCUSSIoN
The	shelflife	of	the	drug	or	any	formulation	is	the	time	on	
which it loses 10 per cent of its potency or biological activity or 
sterility when stored according to manufacturer’s instruction. 
The use of kinetic and predictive studies for establishing 
credible expiration dates for pharmaceutical products are now 
accepted worldwide. 
Our initial studies showed that PAM Cl and atropine 
sulphate drug cartridges are stable for two years at room 
temperature in autoinjector. 
Both atropine sulphate and PAM Cl are currently used 
to protect human from nerve agent poisoning and are the 
recommended drugs for immediate application after nerve 
agent exposure19.  In case of sarin exposure atropine sulphate 
Sample Con. ATR  
(ng/ml)
Ach  
(µg/ml)
% Blocking
ATR+PAM 16 1,2,4 100
ATR+PAM 8 1,2,4 100
ATR+PAM 4 1,2,4 100
ATR+PAM 2 1,2,4 100
ATR+PAM 1 1,2,4 53
Table 2. Selection of atropine sulphate concentration for isolated 
rat ileum against acetylcholine for bioassay
Storage 
temperature (°C) Per cent PI of PAM
storage duration 
(months) 0.5M 1M 2M 4M 8M 16M
30 100.2±0.21 99.8±0.61 98.6±0.29 96.9±0.61 95.3±0.37 88.4±0.62
40 100.4±0.61 96.3±0.37 93.5±0.42 89.3±0.28 85.4±0.26 -
50 99.8±0.73 93.6±0.39 87.6±0.58 - - -
60 98.5±.61 91.6±0.35 84.3±0.54 - - -
Table 1. Percent protective index of various temperature stored sample of PAM Cl + freshly prepared ATR 
against ddVP in vivo
LD50  of DDVP= 11.9 (7.78-18.7) mg/kg.  PI of freshly prepared PAM solution + ATR= 26.9
antagonizes the attachment of acetylcholine at muscarinic 
receptor and PAM Cl reactivates the acethycholinesterase 
inhibited by nerve agent exposure13. In emergencies when there 
is a need to quickly obtain as adequate blood concentration 
of the above drugs and intravenous route of administration is 
not an option, a multicomponent containing autoinjector gives 
many advantages.  In this study we have mixed both the drugs 
in single drug cartridges and develop the new formulation. In 
the development of pharmaceutical dosage form, one of the 
persistent challenges is the assurance of acceptable stability. 
The stability refers to the storage time allowed before any 
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degradation	product	of	the	drug	reaches	to	a	sufficient	level	to	
cause a risk to the patient. The content of PAM Cl and atropine 
sulphate in the cartridge was calculated as a percentage of 
the initial concentration after accelerated stability study.  The 
biological activity of both the drugs was estimated at various 
time intervals on different models to assure the chemical 
analysis.   
In the present experiment no difference was observed 
in the degradation curve from 30–60 °C indicating that the 
reaction follows the same order of kinetics. The temperature 
changes during the accelerated aging can alter the pH and leads 
to non-Arrhenius behavior of drug degradation20. In the study 
the pH of drug solution was noted through out the study and 
that was in the range of 3 to 4, indicating that the degradation 
reaction follows Arrhenius behavior. 
Figure 2 shows log concentration of PAM Cl against 
different time point’s at all four temperatures. This straight 
line	 confirms	 the	 first	 order	 reaction	 for	 the	 degradation	 of	
PAM Cl. It is well known that the drug degradation reaction 
usually	follows	first	order	kinetics	 in	 liquid	preparations21. It 
was observed that higher the storage temperature, the larger the 
degradation constant values obtained. system. Results show that PAM Cl and atropine sulphate 
samples stored at room 30 °C are showing similar PI compared 
to a freshly prepared solution even after eight months. Thus the 
PAM Cl in combination with atropine sulphate is stable for more 
than one year at 30 °C. In previous studies it is reported that the 
administration of PAM along with atropine sulphate results in 
better protection compared to individual protection from each 
drug13,14. In this protection studies also we have used freshly 
prepared atropine solution along with diluted PAM Cl samples, 
even though atropine was incorporated with PAM Cl, After ten 
times dilution the concentration of atropine gets very low and 
not able to produce any effect as recommended dose is quite 
high (10 mg/kg). To overcome this problem we have used freshly 
prepared solution of atropine sulphte for protection studies. 
Results indicate that samples of PAM Cl stored at 40 °C 
was having a PI of more than 94 per cent compared to freshly 
prepared PAM Cl solution even after one month storage and 
start	reduction	in	PI	after	that.	These	biological	findings	match	
with	 our	 analytical	 findings	 in	 which	 also	 concentration	 of	
PAM get less than 90 per cent only after 45 days storage at 
40 °C.
Figure 4 represents the log concentration of atropine 
sulphate against different time point’s at all four temperatures. 
The	straight	line	obtained	confirms	the	first	order	reaction	for	
the degradation. Figure 5 shows degradation reaction constant 
(log K) against the inverse of storage temperature (1/T) for 1 
mg/ml of atropine sulphate solution stored in a combination 
of 300 mg/ml of PAM Cl. With the help of this curve we have 
extrapolated the value of log K for atropine sulphate at 25 °C.
Table 2 represents the effect of various concentrations of 
atropine against acetylcholine (ACh) on isolated rat’s ileum in 
vitro. Data shows that at a minimum dose (2 ng/ml) atropine 
sulphate	is	able	to	block	the	effect	of	4	µg/ml	of	ACh.	On	the	
basis of data represented we have selected 2 ng/ml for further 
studies. 
Table 3 shows the per cent blocking effect of atropine 
sulphate samples stored at various temperatures against ACh 
Figure 3. log K vs 1/T for PAM Cl.
Figure 2. Effect of temperature on log concentration of PAM 
Cl (300 mg/ml) stored in combination with atropine 
sulphate (1 mg/ml).
Extrapolation presupposes that the same rate determing 
reaction is valid at both the accelerated and the extrapolated 
conditions. However, increasing deviation from the 
experimental conditions increases the risk for a change in the 
reaction pattern.  The real time stability data of the sample 
were also calculated by alternatively keeping the samples at 
the room temperature. 
Figure 3 curve shows degradation reaction constant (log 
K) against the inverse of storage temperature (1/T) for 300 mg/ 
ml of PAM Cl solution in combination of 1 mg/ ml of atropine 
sulphate. With the help of this curve we have extrapolated the 
value of log K for PAM Cl at 25 °C. 
Table 1 indicates the percent protective index (PI) of 
stored samples (30-60 °C) of PAM Cl against DDVP in-vivo 
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on rat’s isolated ileum. Biological studies showed that atropine 
sulphate is stable for more than 2 yrs even in addition to PAM 
Cl. Sample contain PAM Cl (300 mg/ml) along with atropine 
i.e. 300 time higher concentration, for observing the effect of 
PAM Cl on isolated rat’s ileum we have used 10 times higher 
dose of PAM (20 ng/ml) compared to atropine against ACh 
and results showed that PAM Cl is not having any effect on 
ACh induced ileum constriction. Thus, this rat’s isolated 
ileum model very well worked as an ideal model for atropine 
bioassay in drug solution. Atropine was found to be stable 
analytically as well as biologically by both the test methods for 
more than 1 year at 30 °C. Kumar14, et al. reported that PAM Cl 
is biologically active for more than 36 months against DDVP 
and DFP, whereas in combination with atropine sulphate the 
stability get reduced for PAM Cl, but no effect was observed in 
atropine sulphate shelf life. 
On the extrapolation stability of PAM Cl (300 mg/ml) in 
combination of atropine sulphate at 25 °C is more than 2 yr 
(810 days). The remaining content of the drug solution after 
storage at 30 °C for 1 year was found to be about 94.32 per 
cent for PAM Cl. Addition 10 per cent  overages (330 mg/ml) 
will double the shelf life of PAM Cl, theoretical data reveal 
that PAM Cl is stable for more than 4 yrs with addition of 
10 per cent overages, atropine sulphate is stable for a longer 
time compared to PAM Cl. On the basis of stressed condition 
storage and real time data it can be predicted that the remaining 
concentration after the long–term study with duration almost 
equal to half of the extrapolated shelf life is much higher than 
90 per cent. 
6. CoNClUSIoN
Preliminary studies indicate that PAM Cl (300 mg/ml) in 
combination with atropine sulphate (1 mg/ml) is stable in clear 
glass cartridges for more than two years at room temperature 
in autoinjectors, with the addition of 10 per cent overages shelf 
life can be further enhanced. 
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